Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.65 |
| ▸ | ALPI | P09923 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | XIAP | P98170 | 1/20 | 0.65 |
| ▸ | NOS3 | P29474 | 3/20 | 0.63 |
| ▸ | NOS1 | P29475 | 3/20 | 0.63 |
| ▸ | NOS2 | P35228 | 3/20 | 0.63 |
| ▸ | PNMT | P11086 | 1/20 | 0.61 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.60 |
| ▸ | KIF11 | P52732 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42993 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL29353281 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL42994 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL30046991 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| Hydrochloric Acid SCHEMBL27547066 | 0.98 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| Hydrochloric Acid SCHEMBL27461719 | 0.98 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| Hydrochloric Acid SCHEMBL27461718 | 0.98 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL28419408 | 0.97 | SLC7A5 (0.71) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL7853137 | 0.89 | SLC7A5 (0.55) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL2314258 | 0.87 | SLC7A5 (0.77) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368224-A1 | BICYCLIC PEPTIDYL PAN-RAS INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2024-11-07 | — | — | US | claimed |
| EP-4358989-A2 | BICYCLIC PEPTIDYL PAN-RAS INHIBITORS | Ohio State Innovation Foundation (US) | 2024-05-01 | — | — | EP | claimed |
| WO-2022271810-A2 | BICYCLIC PEPTIDYL PAN-RAS INHIBITORS | OHIO STATE INNOVATION FOUNDATION (US) | 2022-12-29 | — | — | WO | claimed |
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | claimed |
| US-20160022636-A1 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-28 | — | — | US | claimed |
| EP-2976327-A2 | 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-27 | — | — | EP | claimed |
| EP-2968240-A2 | PHYSIOLOGICAL LIGANDS FOR GPR139 | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | claimed |
| US-20140336216-A1 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-13 | — | — | US | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| WO-2014147021-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | claimed |
| WO-2014152917-A2 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| CN-1199686-C | Sustained release compositions, process for producing the same and utilization thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-05-04 | — | — | CN | claimed |
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | UNIV CALIFORNIA (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260083834-A1 | CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | TRANSFERT PLUS LP (CA) | 2026-03-26 | — | — | US | disclosed |
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | NATIONAL HEALTH RES INST (TW) | 2026-02-19 | — | — | US | disclosed |
| EP-1109831-A2 | CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | disclosed |
| EP-1109827-A2 | BIOACTIVE PEPTIDES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012542-A2 | CYTOTOXIC LACTOFERRIN DERIVATIVES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012541-A2 | CYTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | OPRK1, OPRD1, OPRM1 | SLC7A5 2400/4885PTGS1 405/4885ALPI 3775/4885 |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | SLC7A5 1600/4885PTGS1 109/4885ALPI 2014/4885 |
| US-20240368224-A1 | BICYCLIC PEPTIDYL PAN-RAS INHIBITORS | KRAS, HRAS, NRAS | SLC7A5 2938/4885PTGS1 3299/4885ALPI 2489/4885 |
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | GLP1R, ALB, GIPR | SLC7A5 2195/4885PTGS1 4470/4885ALPI 1697/4885 |
| US-20260083834-A1 | CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | VSIG8, MICA, CD74 | SLC7A5 1741/4885PTGS1 3808/4885ALPI 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.